Literature DB >> 4005562

Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat.

J N Crawley, D W Hommer, L R Skirboll.   

Abstract

Sulfated cholecystokinin octapeptide (CCK) potentiates dopamine-induced hyperlocomotion in the nucleus accumbens of the rat. Immunocytochemical evidence has shown a topographical distribution of terminals containing both CCK and dopamine (DA), within the medial posterior nucleus accumbens. Seven sites within the nucleus accumbens were cannulated and tested for the ability of CCK to enhance the behavioral effects of DA. Close agreement was found between the anatomical sites of CCK-DA coexistence, and the anatomical sites at which CCK potentiated DA-induced hyperlocomotion. Behaviorally inactive sites were found primarily in the anterior nucleus accumbens, where DA-containing terminals do not contain CCK.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4005562     DOI： 10.1016/0006-8993(85)90489-5

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  10 in total

1.  The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.

Authors:  O Valverde; M C Fournie-Zaluski; B P Roques; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

2.  CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.

Authors:  F Weiss; A Ettenberg; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Sexual behavior induction of c-Fos in the nucleus accumbens and amphetamine-stimulated locomotor activity are sensitized by previous sexual experience in female Syrian hamsters.

Authors:  K C Bradley; R L Meisel
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

4.  Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity.

Authors:  S A Josselyn; V P Franco; F J Vaccarino
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

5.  Infusions of cholecystokinin octapeptide into the ventral tegmental area potentiate amphetamine conditioned place preferences.

Authors:  H O Pettit; K Mueller
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Characterization of cholecystokinin octapeptide-stimulated endogenous dopamine release from rat nucleus accumbens in vitro.

Authors:  F H Marshall; S Barnes; R D Pinnock; J Hughes
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

7.  Electrical stimulation of the prefrontal cortex increases cholecystokinin, glutamate, and dopamine release in the nucleus accumbens: an in vivo microdialysis study in freely moving rats.

Authors:  Z B You; T M Tzschentke; E Brodin; R A Wise
Journal:  J Neurosci       Date:  1998-08-15       Impact factor: 6.167

8.  Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats.

Authors:  P T Männistö; A Lang; J Harro; E Peuranen; J Bradwejn; E Vasar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-05       Impact factor: 3.000

Review 9.  Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.

Authors:  Susan Rotzinger; Franco J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

10.  Impairment of stress adaptive behaviours in rats by the CCKA receptor antagonist, devazepide.

Authors:  F Hernando; J A Fuentes; M Ruiz-Gayo
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.